Drug discovery company e-therapeutics has told investors that it enjoyed a "landmark year" despite losses widening from £4.5m to £9.6m.
In results for the year ended January 31, 2022, the Newcastle firm said the losses were mainly attributable to increased research and development expenditure of £6.1m and higher administration costs as it grew.
During the period e-therapeutics said it had made progress across a number of its R&D programmes, including development of its RNAi therapeutics platform, and had filed eleven patents to protect its intellectual property.
